Management of Locally Advanced Rectal Cancer: ASCO Guideline.
Aaron J Scott, Erin B Kennedy, Jordan Berlin...
https://pubmed.ncbi.nlm.nih.gov/39116386/Actively Recruiting
Led by National Cancer Center Hospital East · Updated on 2025-04-03
608
Participants Needed
34
Research Sites
52 weeks
Total Duration
Researchers are evaluating treatments for locally advanced rectal cancer LARC in this multicenter randomized Phase III trial. The study aims to compare two preoperative treatment approaches short-course preoperative radiation SCRT combined with CAPOXIRI versus SCRT combined with CAPOX, testing whether the triplet chemotherapy regimen CAPOXIRI is superior to the doublet regimen CAPOX following SCRT. This research builds on findings that triplet chemotherapy before chemoradiotherapy may improve patient outcomes and seeks to confirm these benefits specifically after SCRT.
CONDITIONS
TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer
Y
Yoshinori Kagawa, MD., PhD
J
Jun Watanabe, MD., PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Cancer Center Hospital East
Lead Sponsor
Japan Agency for Medical Research and Development
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 18 weeks (5 days for radiotherapy plus six 3-week chemotherapy cycles)
Participants receive short-course radiotherapy followed by six cycles of chemotherapy with either CAPOX or CAPOXIRI as preoperative treatment for locally advanced rectal cancer.
1 radiotherapy period and approximately 6 chemotherapy cycles over 18 weeks with associated visits
Duration - Up to 6 weeks after treatment completion
After completing treatment, participants are re-staged to determine response. Those with incomplete response undergo surgery; those with complete or near-complete clinical response may receive non-operative management or surgery based on physician discretion.
1 to 2 visits depending on response evaluation and treatment decision
Duration - Up to 5 years
Participants are monitored with CT, MRI, colonoscopy, and liquid biopsy every 4 months for 2 years, then every 6 months up to 5 years to assess disease status and organ preservation.
Visits every 4 months for 2 years, then every 6 months for up to 5 years
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Aaron J Scott, Erin B Kennedy, Jordan Berlin...
https://pubmed.ncbi.nlm.nih.gov/39116386/Yoshinori Kagawa, J Joshua Smith, Emmanouil Fokas...
https://pubmed.ncbi.nlm.nih.gov/38485756/Yoshinori Kagawa, Koji Ando, Mamoru Uemura...
https://pubmed.ncbi.nlm.nih.gov/39502728/Yoshinori Kagawa, Jun Watanabe, Mamoru Uemura...
https://pubmed.ncbi.nlm.nih.gov/37927927/J Watanabe, Y Kagawa, K Chida...
https://pubmed.ncbi.nlm.nih.gov/41647286/National Cancer Center Hospital East
Lead Sponsor
Japan Agency for Medical Research and Development
Collaborating Sponsor